LBF18107PG01: Difference between revisions
No edit summary |
No edit summary |
||
Line 11: | Line 11: | ||
|Solubility=METHANOL [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]] | |Solubility=METHANOL [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]] | ||
|Mass Spectra=METHOXIME TRI-TMS ETHER METHYL ESTER ; m/e 601(M<SUP><FONT SIZE=-1>+</FONT></SUP>), 586, 570, 530, 511, 496, 480, 440, 421, 390, 350, 300, 294, 263, 217, 205, 191, 73 [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]] | |Mass Spectra=METHOXIME TRI-TMS ETHER METHYL ESTER ; m/e 601(M<SUP><FONT SIZE=-1>+</FONT></SUP>), 586, 570, 530, 511, 496, 480, 440, 421, 390, 350, 300, 294, 263, 217, 205, 191, 73 [[Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115|{{RelationTable/GetFirstAuthor|Reference:Pace-Asciak_CR:Carrara_MC:Domazet_Z:,Biochem. Biophys. Res. Commun.,1977,78,115}}]] | ||
|Source=When prostaglandin I2 or its non-enzymatic degradation product (6-keto-prostaglandin F1<FONT FACE="Symbol">a</FONT>) was infused into man, a major urinary metbolite was 2,3-dinor-6-keto-prostaglandin F1<FONT FACE="Symbol">a</FONT>, a <FONT FACE="Symbol">b</FONT>-oxidation product [[Reference:Needleman_P:Turk_J:Jakschik_BA:Morrison_AR:Lefkowith_JB:,Annu. Rev. Biochem.,1986,55,69|{{RelationTable/GetFirstAuthor|Reference:Needleman_P:Turk_J:Jakschik_BA:Morrison_AR:Lefkowith_JB:,Annu. Rev. Biochem.,1986,55,69}}]];>. | |||
|Chemical Synthesis= {{Image200|XPR1821FT0001.gif}} | |||
|Metabolism= | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} |
Revision as of 22:00, 24 November 2009
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1821 |
LipidMaps | LMFA03010089 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF18107PG01 |
2,3-dinor-6-ketoprostaglandin F_1α | |
---|---|
Structural Information | |
5- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -4-oxopentanoic acid | |
| |
Formula | C18H30O6 |
Exact Mass | 342.204238692 |
Average Mass | 342.42719999999997 |
SMILES | [C@@H]([C@@H](CC(=O)CCC(O)=O)1)(C=C[C@H](O)CCCCC)[C@H](O)C[C@@H]1O |
Physicochemical Information | |
METHANOL Pace-Asciak_CR et al. | |
When prostaglandin I2 or its non-enzymatic degradation product (6-keto-prostaglandin F1a) was infused into man, a major urinary metbolite was 2,3-dinor-6-keto-prostaglandin F1a, a b-oxidation product Needleman_P et al.;>. | |
File:XPR1821FT0001.gif | |
Spectral Information | |
Mass Spectra | METHOXIME TRI-TMS ETHER METHYL ESTER ; m/e 601(M+), 586, 570, 530, 511, 496, 480, 440, 421, 390, 350, 300, 294, 263, 217, 205, 191, 73 Pace-Asciak_CR et al. |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|